Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.

MLA

Endo, Satoshi, et al. “Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.” Journal of Medicinal Chemistry, vol. 63, no. 18, Sept. 2020, pp. 10396–411. EBSCOhost, https://doi.org/10.1021/acs.jmedchem.0c00939.

APA

Endo, S., Oguri, H., Segawa, J., Kawai, M., Hu, D., Xia, S., Okada, T., Irie, K., Fujii, S., Gouda, H., Iguchi, K., Matsukawa, T., Fujimoto, N., Nakayama, T., Toyooka, N., Matsunaga, T., & Ikari, A. (2020). Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer. Journal of Medicinal Chemistry, 63(18), 10396–10411. https://doi.org/10.1021/acs.jmedchem.0c00939

Chicago

Endo, Satoshi, Hiroaki Oguri, Jin Segawa, Mina Kawai, Dawei Hu, Shuang Xia, Takuya Okada, et al. 2020. “Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.” Journal of Medicinal Chemistry 63 (18): 10396–411. doi:10.1021/acs.jmedchem.0c00939.